Tempo Therapeutics, Inc.

An early-stage biotech investor called YK Bioventures plans to raise $100 million, according to an SEC filing on Wednesday. The VC firm has invested in at least five startups, according to public disclosures. That includes bone disorder biotech āshibio; epigenetics company Moonwalk Biosciences , which was co-founded by Feng Zhang; synthetic biology startup Think Bioscience; regenerative medicine-focused Tempo Therapeutics; and hair loss drug developer Pelage Pharmaceuticals . Gary Yeung and Mitchell Kossar are leading the Burlingame, CA-based firm. Yeung previously held executive roles at GGTG Biosciences, xilis, and Erasca, and spent a dozen years at Genentech, which he departed in 2016. Meanwhile, Kossar is president of a life sciences consultancy called First Principles Advisory Group, according to his LinkedIn profile. On his LinkedIn profile, Yeung describes YK as “Beyond Capital,” meaning it provides “industry experience and connections” in addition to money. “We are backed by selected biotech executives and Wall Street investors, partnered with academic and industry luminaries to ‘do well by doing good’ — attributed to Benjamin Franklin,” Yeung wrote on his profile. “We invest in companies that define the future of medicine and patient care.” Yeung and Kossar couldn’t immediately be reached by Endpoints News . So far this year, several other biotech investment firms have put together funds of a similar size — between $100 million and $200 million. It’s a wide range of global investors, including Canadian firm Amplitude , Germany-based Earlybird Health , Australia’s Brandon Capital , Italy-focused XGEN Venture , Boulder, CO-based NewVale Capital , Dublin’s Seroba and Invivo in Barcelona, among others.

First Application of MAP technology in humans to drive regenerative biologic response and spare scarring SAN DIEGO, Sept. 5, 2024 /PRNewswire/ -- Tempo Therapeutics, Inc. ("Tempo"), a leading innovator in tissue engineering and regenerative medicine, today announced the dosing of the first patients in a clinical trial of TT101 (the MOSAIC Trial), the company's lead pipeline candidate for tissue regeneration based on its proprietary MAP technology. TT101 is a first-in-class, flowable and integrative scaffold that has demonstrated non-immunogenic and regenerative tissue responses in large animal studies of soft tissue repair. Based on these compelling preclinical data, TT101 is now being tested in humans to evaluate safety and gather additional information on its ability to potentially regrow large volumes of surgically removed tissue while allowing patients to avoid the formation of disfiguring scars that currently require further intervention. "Enrolling patients in this first clinical trial is a significant milestone for Tempo representing many years of hard work and innovation in bringing the MAP technology from the bench to the bedside," said Westbrook Weaver, PhD, Tempo's Chief Executive Officer and company co-founder. "I am immensely proud of our great team of scientists, engineers, and physicians at Tempo, as well as our investors and partners that have all come together to bring this first-in-class technology to human trials for the first time." The open label, randomized, first-in-human trial is evaluating the safety of TT101 when applied to acute surgical oncology resection sites in the skin after the resection of Basal Cell Carcinomas (BCC) or Squamous Cell Carcinomas (SCC), frequently addressed with Mohs surgery. BCCs and SCCs affect over 5 million patients every year in the United States alone. A significant number of these patients require surgical resection that exposes bone, muscle, or fascia. The recovery of these surgical sites is challenging, costly, and requires continued intervention that can interfere with secondary cancer therapy and negatively affect patient outcomes, especially in those patients also undergoing immunosuppressive treatments or in an immunocompromised state. The Company believes that TT101 and MAP technology have the potential to revolutionize treatment outcomes for surgical oncology patients with complex surgical sites, addressing a large unmet medical need for rapid tissue healing in complex surgical sites. About MAP Technology: The Microporous Annealed Particle (MAP) technology is a first-in-class volumetric flowable porous scaffolding for regenerative medicine. The MAP technology enables Tempo to repurpose established hydrogel polymer components with strong safety profiles by assembling them into a hyper-porous, flowable scaffold format. MAP-based products immediately allow tissue ingrowth and integration upon application. Tissue implants using MAP technology are able to evade the typical inflammatory and scar-forming Foreign Body Response (FBR) and instead promote a regenerative immune response that leads to accelerated formation of vascularized tissue volume. Unlike normal biology and current available products, MAP drives tissue reformation without requiring patient inflammation, unlocking new biological pathways for building tissue inside patients without delivering cells or biologic therapy. About Tempo Therapeutics Tempo Therapeutics is a privately held, clinical-stage technology company pioneering the future of tissue engineering. The Company is leveraging its patented Microporous Annealed Particle (MAP) technology platform with a mission to harness the power of immunomodulation and material science to transform the landscape of medical technology by developing new synthetic biomaterials for use in a variety of surgical reconstruction and therapeutic regenerative applications. For more information about Tempo Therapeutics and its innovative MAP technology platform, please visit . Forward- Looking Statements Any statements in this release that are not historical facts may be considered to be "forward-looking statements." Forward-looking statements are based on management's current expectations and are subject to risks and uncertainties which may cause results to differ materially and adversely from the statements contained herein. Such statements include, but are not limited to, statements regarding the market opportunity for Tempo's product candidates, and the business strategies and development plans of Tempo. Undue reliance should not be placed on forward-looking statements, which speak only as of the date they are made. Except as required by law, Tempo does not undertake any obligation to update any forward-looking statements to reflect new information, events or circumstances after the date they are made, or to reflect the occurrence of unanticipated events. Westbrook Weaver, Ph.D. Chief Executive Officer, Tempo Therapeutics Phone: (619) 202-7445 Email: [email protected] SOURCE Tempo Therapeutics, Inc

2024年3月19日，Tempo Therapeutics成功获得总额1200万美元的A轮融资。本轮融资由知名投资机构Galaxy-Sirius Partners及医疗健康巨头Johnson & Johnson Innovation（强生创新，JJI）联合领投。 Tempo Therapeutics是一家生物材料创新公司，专注于利用前沿的微孔退火颗粒（MAP）技术平台，致力于开发一系列新型合成生物材料，这些材料在手术重建与再生医学领域展现出巨大潜力，正逐步改变医疗技术的面貌。 作为革命性的可注射多孔材料，MAP支架是由精密设计的微凝胶单元构成，在体内通过原位退火过程形成结构稳定的，其细胞尺度的微孔结构为细胞迁移与本体组织整合提供了理想环境，有效促进了生物相容性与组织修复过程。 加州大学教授创业，实现MAP材料微孔隙性和可注射性 2014年，加州大学洛杉矶分校（UCLA）化学与生物分子工程系教授Donald Griffin与拥有丰富执行管理与生命科学研发经验的Westbrook Weaver博士携手，共同创立了Tempo Therapeutics。  公司高管团队,来源于公司官网 其中,Donald Griffin拥有超过14年的深厚研究背景与教授经验，专注于通过优化水凝胶-组织整合来推动非细胞及细胞治疗在临床应用上的进步，巧妙地将微尺度几何控制与现代化学技术相结合，设计出具有革新意义的生物材料。 而Westbrook Weaver博士拥有超过7年的执行管理经验和15年的生命科学研发经验。根据Westbrook回忆，他与Donald的相识发生在加州大学洛杉矶分校的生物工程系足球队。当时，Donald Griffin专注于研究组织工程，他则致力于研究微流体。尽管这两个领域在生物工程中通常各自独立，但它们的结合却催生了一种创新技术——微孔退火颗粒（MAP）核心技术，这成为了Tempo Therapeutics创办的基础。 2015年，两人在《Nature Materials》上发表了题为“Accelerated wound healing by injectable microporous gel scaffolds assembled from annealed building blocks”的研究论文，展示了一种可注射的、相互连接的微孔凝胶支架，这种支架由退火的微凝胶构建块组装而成，微凝胶构建块的化学和物理性质可以通过微流体制造来定制。 研究数据显示：在体外，支架形成过程中纳入的细胞在48小时内增殖并形成广泛的三维网络。在体内，支架促进细胞迁移，实现5天内快速的皮肤组织再生和组织结构形成。这些退火凝胶支架的微孔隙性和可注射性相结合，将为体内组织再生和形成提供新的途径。 据了解，Tempo Therapeutics正在利用MAP技术，将传统水凝胶聚合物重新构造成超多孔、可流动的支架，实现了组织即刻向内生长与整合，有效避免了异物反应，促进了再生免疫反应和血管化组织体积的快速形成。    布局五条产品管线， 特别关注再生市场 MAP支架平台凭借其与宿主组织快速整合的能力及低免疫原性特性，已被证实在加速真皮伤口愈合、脑卒中腔治疗、血运重建、间充质干细胞递送、组织膨胀治疗及声门功能不全修复等多个再生医学领域展现出卓越效果。 Tempo Therapeutics也正积极利用其自主研发的新型MAP技术，开发一系列前沿的组织工程与再生医学产品。截至目前，公司已构建起五条产品管线，覆盖从复杂手术伤口修复到医学美容、软骨再生乃至疫苗开发的11个应用场景。 其中，Tempo Therapeutics特别关注再生市场，根据PrecedenceResearc的数据，2021年全球再生医学市场规模为200.4 亿美元，预计到 2030 年将达到1255.4亿美元左右，2022年至2030年的复合年增长率为16.2%。Tempo Therapeutics旗下相关产品管线TT101-Biosurgery发展最快，已经进入临床试验阶段。 公司产品管线,来源于公司官网 TT101-Biosurgery产品专为解决复杂手术伤口及医疗器械植入后的组织愈合难题而设计。细胞迁移是伤口愈合与组织再生的关键环节，而传统愈合剂往往因阻碍细胞迁移而效果有限。TT101-Biosurgery通过创新的微孔凝胶系统，优化了组织-装置接口，为细胞迁移与组织再生提供了理想环境。 根据Tempo Therapeutics披露，猪的伤口床被一种精心设计的微孔凝胶完全填充后，组织学横切面检查表明，微孔凝胶在处理后5天内即完全填充伤口床，并几乎完全降解；在组织纤维化的病理评分中，微孔支架治疗的伤口显示出更少的胶原纤维束排列和密集度，表明其组织结构更偏向于非纤维性瘢痕组织， 值得一提的是，在一项为期38天的对比实验显示，与无孔可流动水凝胶（化学成分与Oasis®SIS基质相同，但无微孔结构）相比，微孔凝胶注射在注射部位实现了几乎完整的组织整合，且未检测到炎症或MNGC的存在，表明其优异的生物相容性和组织融合能力。同时，注射部位还形成了具有大血管壁和网状真皮组织的非纤维性组织，进一步证明了微孔凝胶在促进皮肤内组织再生方面的优势。 Donald R. Griffin公开表示：“减缓MAP支架的降解速度可以防止孔隙闭合，并在组织生长过程中为其提供额外的支持，从而提高组织质量”。而经过技术修改的水凝胶能够会被用来更快、更自然地修复伤口，甚至有助于疫苗开发。目前，Tempo Therapeutics还在开发联合给药、同种异体细胞植入和下一代疫苗技术。   吸金1200万美元， 将管线推向临床试验 有了A轮这笔资金，Tempo Therapeutics将首次进入基于MAP技术的外科支架的临床试验。作为基于MAP技术的组织支架的唯一开发商，Tempo Therapeutics正准备通过建立其两个主要产品的安全性和有效性来达到关键的发展里程碑:TT101-Biosurgery:complex surgical wound，用于暴露骨、肌腱或筋膜的复杂手术部位;TT101-Biosurgery:abdomial用于筋膜切口部位加固。 “Tempo Therapeutics通过真正的再生医疗技术突破，处于改变医疗结果的最前沿。我们立即看到了一项革命性的、颠覆性的技术与巨大的市场机会相结合，”领导本轮融资的Galaxy-Sirius Partners的马蒂·桑兹(Marty Sands)说道，“Tempo Therapeutics拥有一项平台专利技术，可以显著改变大量外科手术的医疗结果。” 近年来，水凝胶作为一类独特的智能材料，凭借其独特的结构性质与环境刺激响应性能，在农业、医药、工业等多个领域展现出广泛的应用前景。随着科技的进步与创新的推动，新型结构与性质的水凝胶不断涌现，为各行业的转型升级提供了强有力的技术支持。 目前，尽管国内并无基于MAP技术的水凝胶材料的创新案例披露，不过，中国市场水凝胶行业的发展也颇为引人注目。据共研网数据，自2012年至2022年十年间，中国水凝胶市场规模实现了显著增长，从22.8亿元攀升至62.8亿元，年复合增长率高达10.66%。 中国水凝胶市场主要本土厂商包括长春吉原生物科技、珠海国佳新材、惠州华阳医疗器械等。值得一提的是，华诺生物基于超分子非共价交联的胶体网络水凝胶材料设计与制备技术研发自修复水凝胶材料以原料安全无毒、力学强度高、制作简便，且具备可注射、可打印、可塑性、可降解吸收等优势呈现“黑马”之势。 如果您想对接文章中提到的项目，或您的项目想被动脉网报道，或者发布融资新闻，请与我们联系；也可加入动脉网行业社群，结交更多志同道合的好友。 近 期 推 荐 声明：动脉网所刊载内容之知识产权为动脉网及相关权利人专属所有或持有。未经许可，禁止进行转载、摘编、复制及建立镜像等任何使用。 动脉网，未来医疗服务平台